| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | FLCN |
| Uniprot No | Q8NFG4 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-342aa |
| 氨基酸序列 | MNAIVALCHFCELHGPRTLFCTEVLHAPLPQGDGNEDSPGQGEQAEEEEGGIQMNSRMRA HSPAEGASVESSSPGPKKSDMCEGCRSLAAGHPGYISHDKETSIKYVSHQHPSHPQLFSI VRQACVRSLSCEVCPGREGPIFFGDEQHGFVFSHTFFIKDSLARGFQRWYSIITIMMDRI YLINSWPFLLGKVRGIIDELQGKALKVFEAEQFGCPQRAQRMNTAFTPFLHQRNGNAARS LTSLTSDDNLWACLHTSFAWLLKACGSRLTEKLLEGAPTEDTLVQMEKLAGEAGVLLPGP WPGWPWGGTSCLLSWQESLREGNAALNQPRTSLREAHPPISV |
| 预测分子量 | kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于FLCN重组蛋白的3篇代表性文献(注：文献为示例性虚构，实际引用请核实真实来源)：
---
1. **文献名称**：*Recombinant FLCN expression and its role in mTOR signaling regulation*
**作者**：Smith A, et al.
**摘要**：研究通过大肠杆菌系统成功表达重组FLCN蛋白，并验证其与FNIP1/2的相互作用，揭示了FLCN通过调控mTORC1活性影响细胞代谢的分子机制。
2. **文献名称**：*Structural characterization of FLCN recombinant protein in Birt-Hogg-Dubé syndrome*
**作者**：Lee B, et al.
**摘要**：利用X射线晶体学解析了重组FLCN蛋白的三维结构，发现其C端结构域突变与BHD综合征的致病性相关，为疾病治疗提供了潜在靶点。
3. **文献名称**：*FLCN recombinant protein rescues autophagy defects in renal carcinoma cells*
**作者**：Chen X, et al.
**摘要**：通过哺乳动物细胞表达系统制备功能性FLCN重组蛋白，证实其可恢复肾癌细胞自噬异常，抑制肿瘤增殖，提示其治疗应用潜力。
---
如需真实文献，建议检索PubMed/Google Scholar关键词：**"FLCN recombinant protein" "expression" "mTOR" "Birt-Hogg-Dubé"**。
**Background of FLCN Recombinant Protein**
The folliculin (FLCN) gene, located on chromosome 17p11.2. encodes a tumor suppressor protein implicated in regulating cell growth, metabolism, and autophagy. Mutations in FLCN are linked to Birt-Hogg-Dubé (BHD) syndrome, a rare autosomal dominant disorder characterized by skin lesions, renal tumors, and pulmonary cysts. The FLCN protein interacts with binding partners folliculin-interacting protein 1 (FNIP1) and FNIP2. forming a complex that modulates the mTOR (mechanistic target of rapamycin) signaling pathway—a critical regulator of cellular responses to nutrient availability and stress.
Recombinant FLCN protein is produced using biotechnological methods, such as expression in bacterial (e.g., *E. coli*) or mammalian cell systems, followed by purification via affinity chromatography. This engineered protein retains functional domains necessary for studying its biological roles, including interactions with FNIP1/2 and mTOR pathway components. Researchers use recombinant FLCN to investigate its molecular mechanisms in vitro and in vivo, such as its involvement in lysosomal regulation, energy sensing, and tumor suppression.
Studies leveraging recombinant FLCN have advanced understanding of its dual role in both inhibiting and activating mTOR-dependent processes, depending on cellular context. Dysregulation of FLCN is associated with renal carcinogenesis and metabolic disorders, making it a potential therapeutic target. Additionally, recombinant FLCN aids in developing diagnostic tools for BHD syndrome and screening compounds to restore its function in mutation-bearing cells. Challenges remain in fully elucidating its post-translational modifications and tissue-specific interactions, underscoring the need for further research using high-purity recombinant variants.
×
